Roivant Sciences stock is trading -32.69% below its average target price of $16.75 after marking a 3.8% during today's afternoon session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $12.0 to $22.0 per share.
Roivant Sciences has an average level of shares sold short, at 9.1% of its total share float. The stock's short ratio (also called days to cover) is 9.19. Since 30.3% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Institutional investors own 83.5% of Roivant Sciences's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Roivant Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | QVT Financial LP | 10% | 65,793,779 | $741,824,833 |
| 2025-03-31 | SB Investment Advisers (UK) LTD | 9% | 61,852,718 | $697,389,371 |
| 2025-03-31 | FMR, LLC | 8% | 51,666,511 | $582,539,891 |
| 2025-03-31 | Viking Global Investors, L.P. | 7% | 46,013,752 | $518,805,036 |
| 2025-03-31 | Blackrock Inc. | 6% | 41,659,488 | $469,710,711 |
| 2025-03-31 | Vanguard Group Inc | 6% | 40,767,590 | $459,654,561 |
| 2025-03-31 | Morgan Stanley | 5% | 35,926,759 | $405,074,194 |
| 2025-03-31 | State Street Corporation | 3% | 18,861,653 | $212,665,130 |
| 2025-03-31 | Rubric Capital Management LP | 3% | 17,767,076 | $200,323,775 |
| 2025-03-31 | Patient Square Capital LP | 2% | 12,480,000 | $140,711,995 |
